DK641889A - Anvendelse af en blodpladeaktiveringsfaktorantagonist i kombination med monoklonale eller polyklonale antistoffer i et farmaceutisk praeparat til behandling af endotoksisk chok hos pattedyr - Google Patents

Anvendelse af en blodpladeaktiveringsfaktorantagonist i kombination med monoklonale eller polyklonale antistoffer i et farmaceutisk praeparat til behandling af endotoksisk chok hos pattedyr Download PDF

Info

Publication number
DK641889A
DK641889A DK641889A DK641889A DK641889A DK 641889 A DK641889 A DK 641889A DK 641889 A DK641889 A DK 641889A DK 641889 A DK641889 A DK 641889A DK 641889 A DK641889 A DK 641889A
Authority
DK
Denmark
Prior art keywords
monoclonal
combination
polycllonal
endotoxic shock
antibodies
Prior art date
Application number
DK641889A
Other languages
English (en)
Other versions
DK641889D0 (da
Inventor
Allan Wissner
Suresh S Kerwar
Constance Kohler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of DK641889D0 publication Critical patent/DK641889D0/da
Publication of DK641889A publication Critical patent/DK641889A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Disintegrating Or Milling (AREA)
  • Percussive Tools And Related Accessories (AREA)
  • Thermistors And Varistors (AREA)
  • Measurement Of Force In General (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Surgical Instruments (AREA)
DK641889A 1988-12-19 1989-12-18 Anvendelse af en blodpladeaktiveringsfaktorantagonist i kombination med monoklonale eller polyklonale antistoffer i et farmaceutisk praeparat til behandling af endotoksisk chok hos pattedyr DK641889A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28620188A 1988-12-19 1988-12-19

Publications (2)

Publication Number Publication Date
DK641889D0 DK641889D0 (da) 1989-12-18
DK641889A true DK641889A (da) 1990-06-20

Family

ID=23097534

Family Applications (1)

Application Number Title Priority Date Filing Date
DK641889A DK641889A (da) 1988-12-19 1989-12-18 Anvendelse af en blodpladeaktiveringsfaktorantagonist i kombination med monoklonale eller polyklonale antistoffer i et farmaceutisk praeparat til behandling af endotoksisk chok hos pattedyr

Country Status (18)

Country Link
US (1) US5124147A (da)
EP (1) EP0374510B1 (da)
JP (1) JP2931344B2 (da)
KR (1) KR0148680B1 (da)
AT (1) ATE147634T1 (da)
AU (1) AU624457B2 (da)
CA (1) CA2005670A1 (da)
DE (1) DE68927671T2 (da)
DK (1) DK641889A (da)
ES (1) ES2096553T3 (da)
FI (1) FI896046A0 (da)
GR (1) GR3022969T3 (da)
IL (1) IL92471A (da)
NZ (1) NZ231725A (da)
PH (1) PH31376A (da)
PT (1) PT92596B (da)
SG (1) SG43205A1 (da)
ZA (1) ZA899685B (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5147864A (en) * 1988-12-19 1992-09-15 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
US4983592A (en) * 1988-12-19 1991-01-08 American Cyanamid Co. Bis-arylphosphate ester antagonists of platelet activating factor
US5231091A (en) * 1988-12-19 1993-07-27 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
AU3244693A (en) * 1991-12-17 1993-07-19 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
US6193969B1 (en) 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
JPH09507578A (ja) * 1994-01-14 1997-07-29 ジェネンテク，インコーポレイテッド インスリン受容体チロシンキナーゼインヒビターに対するアンタゴニスト
CA2185162A1 (en) 1994-03-07 1995-09-14 Robert F. Halenback (Deceased) Compositions for the inhibition of tnf formation and uses thereof
US5939269A (en) * 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
CA2210484C (en) * 1995-01-23 2012-12-04 Xenotech Incorporated Composition to ameliorate osteolysis and metastasis
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
KR20150006085A (ko) 2006-04-05 2015-01-15 애브비 바이오테크놀로지 리미티드 항체 정제
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
JP5836940B2 (ja) 2009-06-26 2015-12-24 ソリシメド・バイオファーマ・インコーポレーテッド ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148879A (en) * 1977-12-23 1979-04-10 Nelson Research & Development Company Inhibition of platelet aggregation with selected phosphonic and phosphinic acid esters

Also Published As

Publication number Publication date
EP0374510A1 (en) 1990-06-27
PT92596A (pt) 1990-06-29
JP2931344B2 (ja) 1999-08-09
ATE147634T1 (de) 1997-02-15
SG43205A1 (en) 1997-10-17
KR0148680B1 (ko) 1998-08-17
GR3022969T3 (en) 1997-06-30
NZ231725A (en) 1992-12-23
AU4688589A (en) 1990-06-21
DE68927671D1 (de) 1997-02-27
PT92596B (pt) 1996-06-28
ES2096553T3 (es) 1997-03-16
DK641889D0 (da) 1989-12-18
AU624457B2 (en) 1992-06-11
CA2005670A1 (en) 1990-06-19
JPH02212435A (ja) 1990-08-23
ZA899685B (en) 1990-09-26
PH31376A (en) 1998-10-29
IL92471A0 (en) 1990-08-31
FI896046A0 (fi) 1989-12-18
DE68927671T2 (de) 1997-05-07
IL92471A (en) 1995-06-29
EP0374510B1 (en) 1997-01-15
US5124147A (en) 1992-06-23
KR900009097A (ko) 1990-07-02

Similar Documents

Publication Publication Date Title
DK641889A (da) Anvendelse af en blodpladeaktiveringsfaktorantagonist i kombination med monoklonale eller polyklonale antistoffer i et farmaceutisk praeparat til behandling af endotoksisk chok hos pattedyr
DE68920693D1 (de) Gefriergetrocknete Zusammensetzung, die ein mit Meerrettichperoxydase markiertes Fab'-Fragment eines gegen menschliches Beta-Interferon gerichteten Antikörpers und Trehalose enthält; EIA Kit, der diese Zusammensetzung enthält.
DK0605442T3 (da) Rekombinante antistoffer til human terapi
DK486588D0 (da) Konjungater af cytokininer med immunglobuliner
DK0732101T3 (da) Anvendelse af L-deprenyl til forsinkelse af alderdomssvækkelse af immunsystemfunktionen hos pattedyr
DK149990D0 (da) Familie af modificerede antistoffer med hoej affinitet til cancerbehandling
DE69214656D1 (de) Therapeutisches verfahren zur behandlung von iddm
ATE76579T1 (de) Interferon-zusammensetzungen.
DK81691A (da) Fremgangsmaade til forhindring eller reduktion af eosinofili
ES2062762T3 (es) Metodo para tratar el choque septico.
FI924215A0 (fi) Anvaendningen av il-4 foer oekning av immunreaktionen foerorsakad infektiosa antigen aemnen.
FI874273A (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
DE3787239D1 (de) Komplementabhängiger zytolytischer monoklonaler Antikörper gegen Trichomonas vaginalis und seine therapeutische und diagnostische Verwendung.
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
DE3679255D1 (de) Behandlung chronischer entzuendungskrankheiten.
ES2038578T1 (es) Utilizacion de inmunoglobulinas g humanas, o de fragmentos fc de estas, como medicamento preparatorio para la administracion al hombre de anticuerpos monoclonales.
ATE126704T1 (de) Bcrf1-antagonisten zur behandlung von epstein- barr-virus-infektionen.
IT1213576B (it) Composizione polipeptidica utile per la preparazione di vaccini antimalaria e di kits diagnostici per la determinazione di anticorpi antimerozoite.
DK0427633T3 (da) Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer
IT8148480A0 (it) Composizione terapeutica e sistema per il trattamento extracorporeo di sangue intero
NO931636D0 (no) Synergistisk terapi med kombinasjoner av anti-tumor antistoffer og biologisk aktive forbindelser

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment